

Minutes of the Institute Biosafety Committee Meeting

December 10, 2025

Convened at: 1:00 pm and Adjourned at 1:40 pm

Present: Drs. Gelman (Chair), Foster, Gerber, Ding, Ionov, McGray, Thanavala, Mr. Hartley, Ms. Holtz, and Mr. Korytko.

Absent: Ms Keough, Ms Oliver and Mr. Atwal

ORSP Staff: Ms Pusateri, Ms Herter Ms. Bennett and Mr. Caruana

Guests: None.

Meeting Place: Virtual meeting/Teams.

Minutes of November 12, 2025 were approved.

Vote: Unanimous.

Adverse Event/Accident/Incident Report

November Employee Health Service report; no incidents.

ORSP - No reports.

Old Business

1. Safety Story; this months story highlighted safety and good communication.
2. Laboratory inspections; May, September and October are pending:
 - Laboratories were visited May 15th with Dr. McGray joining the team.
 - a. Chandra level 2 lab: OES will follow up (see check list for details).
 - b. Sung level 2+ lab: OES will follow up (see check list for details).
 - Laboratories were visited September 4th with Dr. McGray joining the team:
 - a. Paragh level 2 lab: OES will follow up (see checklist for details).
 - b. Das level 2 lab: OES will follow up (see checklist for details).
 - Laboratories were visited October 9th with Dr. Ionov joining the team.
 - a. Atanassov level 2+ lab: OES will follow up (see checklist for details).
3. The administrative staff reviewed an updated Continuing review question with the committee. The update will request further information when an IRB related continuing review is required. Questions were reviewed and approved. The administrative staff will work with Key Solutions personnel to get the questions updated. **Update 12/10:** Question has been updated in Key.

New Business:

1. 4 Laboratories were visited November 13th with Dr. McGray joining the team.
 - a. Olejniczak BSL 2+ lab: No follow up required.
 - b. Yau BSL2+ lab: OES will follow up (see checklist for details).
 - c. Fang BSL2+ lab: No follow up required.
 - d. Li, Q BSL2+ lab: No follow up required.

The next inspection dates will be Thursday December 11th with Dr. Ding joining the team and Thursday January 8th with Dr. McGray joining the team.
2. NIH is requesting verification of meeting minutes being posted. The administrative staff will update the NIH website with our URL where the minutes are posted.
3. Meeting dates for 2026 were reviewed. There are three dates which may be necessary to modify due to holiday. Once clarified; all dates will be sent to committee members via Microsoft Outlook.

Protocol review:

5 Biosafety applications were reviewed.

1 Protocol referenced Virus

Application for Lab/1492M: Approved.

Reviewed by Dr. Ionov

The Initial application for Lab/1492M, 25-11-1702 entitled: "McLean Laboratory." PI: McLean, Karen was approved.

The purpose of this protocol is to dissect how DNA damage repair mechanisms affect ovarian cancer progression.

Biosafety agents include: lentivirus, olaparib, fulvestrant, trametinib, carboplatin, capivasertib

1 Protocol referenced gene editing

Application for lab: Tabled.

Reviewed by Dr. McGray

The Initial application for Lab, 24-02-1571 entitled: "The role of interferon signaling in the anti-cancer activity of chromatin damaging (CD) agents." PI: Gurova, Katerina was Tabled.

The purpose of this protocol is to develop and characterize drugs that kill cancer cells via chromatin damage.

Biosafety agents include: lentivirus, doxorubicin, aclarubicin

1 Protocol reference rDNA and biologicals.

Application for Lab/1372M: Approved pending.

Reviewed by Dr. Ding

The Initial application for Lab/1372M, 25-07-1680 entitled: "Stablewski Lab Biosafety." PI: Stablewski, Aimee was approved pending designated member review of a revised application.

The purpose of this protocol is to identify and characterize genes that control therapy resistance in ovarian cancer.

Biosafety agents include: Paclitaxel, cisplatin

Exempt from full committee review: None.

Amendments:

Application for Lab/1384M: Approved.

Reviewed by Dr. Gelman

The amendment to Lab based/1384M 25-01-1646 entitled: "Mechanisms of Carcinogenesis and Novel Avenues for Therapeutic Intervention" PI: Knudsen, Erik was approved as Exempt from full committee review 11/14/2025.

Biosafety agents used include: 2 new Cell lines.

Application for Lab/1395M: Approved.

Reviewed by Dr. Gelman

The amendment to Lab based/1395M 24-07-1608 entitled: "Qiang Li Biosafety Application" PI: Li, Qiang was approved as Exempt from full committee review 11/26/2025.

Biosafety agents used include: Compound; gemcitabine.

See attached for complete list.

Respectfully Submitted,

A handwritten signature in blue ink, reading "Irwin Gelman". The signature is fluid and cursive, with the first name "Irwin" and last name "Gelman" clearly distinguishable.

Irwin Gelman, PhD
Institute Biosafety Committee Chair
Director of Research Integration; Professor of
Oncology